In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s ...

Immunovant's (NASDAQ:IMVT) stock and Roivant Sciences (ROIV) stock fall after trial data for the former's autoimmune disease ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

In Roivant, Pfizer has a partner with "a proven track record in late-stage inflammation and immunology drug development," said the big pharma's chief scientific officer Mikael Dolsten. Hiving off ...

Roivant Sciences (ROIV) announced that the members of the Board of Directors of Arbutus Biopharma (ABUS) have resigned and been replaced. As of the date hereof, Roivant beneficially owns and ...

Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...

Explore Roivant Sciences stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ROIV. Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9 ...

Pharmaceutical companies had more patents ... while other potential medicines would languish. In 2014, he founded Roivant Sciences to buy or license promising drugs that weren’t a priority ...

BASEL, Switzerland and LONDON and NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (“Roivant”) today announced that the members of the Board of Directors of Arbutus Biopharma ...

In its fourth quarter 2024 investor letter, Tourlite Capital Management emphasized stocks such as Roivant Sciences Ltd. (NASDAQ:ROIV). Roivant Sciences Ltd. (NASDAQ:ROIV) is a commercial-stage ...